The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Pathway to global elimination of hepatitis B: HBV cure is just the first step
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000430. Online ahead of print.
1Disease Elimination, Burnet Institute, Melbourne Australia.
2Department Gastroenterology, St Vincent's Hospital Melbourne Australia.
3Department Medicine, University of Melbourne, Melbourne Australia.
4Department Epidemiology and Preventive Medicine, Monash University, Melbourne Australia.
5Department Global health and infectious diseases, Menzies school of public health, Darwin Australia.
6World Hepatitis Alliance.
7Department Paediatrics, Ain Shams University, Cairo Egypt.
8Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto Canada.
9Department Medicine, University of Auckland, Auckland New Zealand.
10Sorbonne Université, IPLESP, Saint-Antoine Hospital, AP-HP, Paris France.
11Global HIV, hepatitis and STI programme, World Health Organisation.
12Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
13Department Hepatology and Liver Transplantation, Austral University Hospital, Buenos Aires Argentina.
14Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, Australia.
15University of Sydney Institute for Infectious Diseases, University of Sydney, Australia.
16Victorian Infectious Diseases Reference Laboratory (VIDRL), Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
17Department Infectious Diseases, Alfred Hospital, Melbourne Australia.
18Department Infectious Diseases, School of Population and Global Health, University of Melbourne, Melbourne Australia.
Abstract
Hepatitis B (HBV) is a major cause of global morbidity and mortality and the lead cause of liver cancer worldwide. Significant advances have recently been made towards development of a finite HBV treatment that achieves permanent loss of HBsAg and HBV DNA (so-called "HBV cure"), which could provide the means to eliminate HBV as a public health threat. However, HBV cure is just one step toward achieving WHO HBV elimination targets by 2030 and much work must be done now to prepare for successful implementation of HBV cure. In this review, we describe the required steps to rapidly scale-up future HBV cure equitably. We present key actions required for successful HBV cure implementation, integrated within the WHO GHSS 2022-2030 framework. Finally, we highlight what can be done now to progress towards the 2030 HBV elimination targets using available tools to ensure we are preparing, but not waiting, for cure.